{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:39:04Z","timestamp":1790314744138,"version":"4.1.0"},"reference-count":80,"publisher":"Harborside Press, LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"\n Background:<\/jats:bold>\n Carcinoid syndrome (CS), the most prevalent neuroendocrine tumor (NET)\u2013related hormonal syndrome, is associated with impaired survival. However, the contribution of NET-specific death in patients with this syndrome is currently unknown. This study aimed to evaluate overall survival (OS), prognostic factors, and causes of death in patients with CS.\n Patients and Methods:<\/jats:bold>\n We retrospectively included patients with CS treated between 1995 and 2021 at our ENETS Center of Excellence. We used Kaplan-Meier curves and log-rank tests to perform survival analyses, and a Cox proportional hazards model to calculate mortality hazard ratios (HRs).\n Results:<\/jats:bold>\n A total of 295 of 427 included patients with CS died during follow-up, and cause of death was recorded in 255 patients. In 231 (90.6%) patients, the cause of death was NET-specific. Median OS was 7.1 years, and 65.1% and 34.1% of CS patients were alive at 5 and 10 years, respectively. Multivariate analysis identified age (HR, 1.06;\n P<\/jats:italic>\n <.001), WHO tumor grade 2 (HR, 2.11;\n P<\/jats:italic>\n =.01), plasma chromogranin A (CgA) level of 200 to 940 \u00b5g\/L (HR, 1.64;\n P<\/jats:italic>\n =.04), CgA level >940 \u00b5g\/L (HR, 3.18;\n P<\/jats:italic>\n <.001), and primary lung NET (HR, 1.77;\n P<\/jats:italic>\n =.008) as negative predictors of survival. The presence of carcinoid heart disease (HR, 1.01;\n P<\/jats:italic>\n =.97) was not associated with OS in a multivariate model due to interaction with CgA levels.\n Conclusions:<\/jats:bold>\n Patients with CS are likely to succumb to their disease, with >90% of mortality being NET-specific. Age, tumor grade, primary lung origin, and CgA levels were independent predictors of mortality. These findings indicate that there is an urgent need for advances in therapeutic options for patients with CS.\n <\/jats:p>","DOI":"10.6004\/jnccn.2025.7130","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:37:32Z","timestamp":1773088652000},"source":"Crossref","is-referenced-by-count":3,"title":["Determining Prognosis in Patients With Carcinoid Syndrome: A Retrospective Single-Center Cohort Study"],"prefix":"10.6004","volume":"24","author":[{"given":"Merijn C.F.","family":"Mulders","sequence":"first","affiliation":[{"name":"Section of Endocrinology, Department of Internal Medicine, ENETS Center of Excellence, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine F.","family":"Maas","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Department of Internal Medicine, ENETS Center of Excellence, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Feelders","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Department of Internal Medicine, ENETS Center of Excellence, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter W.","family":"de Herder","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Department of Internal Medicine, ENETS Center of Excellence, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Hofland","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Department of Internal Medicine, ENETS Center of Excellence, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"JAMA Oncol","first-page":"1335","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari A","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017;3:1335\u20131342"},{"key":"B2","series-title":"Lancet Reg Health Eur","first-page":"100510","article-title":"Incidence and survival of neuroendocrine neoplasia in England 1995-2018: a retrospective, population-based study","volume":"23","author":"White BE","year":"2022","unstructured":"White BE, Rous B, Chandrakumaran K, Incidence and survival of neuroendocrine neoplasia in England 1995-2018: a retrospective, population-based study. Lancet Reg Health Eur 2022;23:100510."},{"key":"B3","series-title":"Lancet Oncol","first-page":"525","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin DM","year":"2017","unstructured":"Halperin DM, Shen C, Dasari A, Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol 2017;18:525\u2013534."},{"key":"B4","series-title":"J Oncol","first-page":"8341426","article-title":"Update on pathophysiology, treatment, and complications of carcinoid syndrome","volume":"2020","author":"Clement D","year":"2020","unstructured":"Clement D, Ramage J, Srirajaskanthan R. Update on pathophysiology, treatment, and complications of carcinoid syndrome. J Oncol 2020;2020:8341426."},{"key":"B5","series-title":"Neuroendocrinology","first-page":"263","article-title":"Carcinoid heart disease: from pathophysiology to treatment \u2013 \u2018something in the way it moves.\u2019","volume":"101","author":"Grozinsky-Glasberg S","year":"2015","unstructured":"Grozinsky-Glasberg S, Grossman AB, Gross DJ. Carcinoid heart disease: from pathophysiology to treatment \u2013 \u2018something in the way it moves.\u2019 Neuroendocrinology 2015;101:263\u2013273."},{"key":"B6","series-title":"Endocr Rev","first-page":"351","article-title":"What is carcinoid syndrome? A critical appraisal of its proposed mediators","volume":"45","author":"Mulders MCF","year":"2024","unstructured":"Mulders MCF, de Herder WW, Hofland J. What is carcinoid syndrome? A critical appraisal of its proposed mediators. Endocr Rev 2024;45:351\u2013360."},{"key":"B7","series-title":"J Chromatogr B Biomed Sci Appl","first-page":"33","article-title":"Clinical chemistry of serotonin and metabolites","volume":"747","author":"Kema IP","year":"2000","unstructured":"Kema IP, de Vries EG, Muskiet FA. Clinical chemistry of serotonin and metabolites. J Chromatogr B Biomed Sci Appl 2000;747:33\u201348."},{"key":"B8","series-title":"Eur J Cancer","first-page":"1975","article-title":"Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry","volume":"49","author":"Korse CM","year":"2013","unstructured":"Korse CM, Taal BG, van Velthuysen ML, Visser O. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer 2013;49:1975\u20131983."},{"key":"B9","series-title":"Eur J Cancer","first-page":"252","article-title":"Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: a population-based study","volume":"172","author":"Pole\u00e9 IN","year":"2022","unstructured":"Pole\u00e9 IN, Hermans BCM, van der Zwan JM, Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: a population-based study. Eur J Cancer 2022;172:252\u2013263."},{"key":"B10","series-title":"Am J Clin Oncol","first-page":"668","article-title":"Competing mortality in patients with neuroendocrine tumors","volume":"42","author":"Low SK","year":"2019","unstructured":"Low SK, Giannis D, Bahaie NS, Competing mortality in patients with neuroendocrine tumors. Am J Clin Oncol 2019;42:668\u2013674."},{"key":"B11","series-title":"Pancreas","first-page":"47","article-title":"Causes of death after neuroendocrine tumors diagnosis: a US population-based analysis","volume":"50","author":"Sonbol MB","year":"2021","unstructured":"Sonbol MB, Saad AM, Gonzalez-Velez M, Causes of death after neuroendocrine tumors diagnosis: a US population-based analysis. Pancreas 2021;50:47\u201353."},{"key":"B12","series-title":"J Natl Compr Canc Netw","first-page":"935","article-title":"Risk of cancer-specific death for patients diagnosed with neuroendocrine tumors: a population-based analysis","volume":"19","author":"Hallet J","year":"2021","unstructured":"Hallet J, Law C, Singh S, Risk of cancer-specific death for patients diagnosed with neuroendocrine tumors: a population-based analysis. J Natl Compr Canc Netw 2021;19:935\u2013944."},{"key":"B13","series-title":"Neuroendocrinology","first-page":"547","article-title":"Clinical features and prognosis of patients with carcinoid syndrome and carcinoid heart disease: a retrospective multicentric study of 276 patients","volume":"112","author":"Fijalkowski R","year":"2022","unstructured":"Fijalkowski R, Reher D, Rinke A, Clinical features and prognosis of patients with carcinoid syndrome and carcinoid heart disease: a retrospective multicentric study of 276 patients. Neuroendocrinology 2022;112:547\u2013554."},{"key":"B14","series-title":"ESMO Open","first-page":"103959","article-title":"Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers","volume":"9","author":"Algeri L","year":"2024","unstructured":"Algeri L, Falkman L, Spada F, Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers. ESMO Open 2024;9:103959."},{"key":"B15","series-title":"Neuroendocrinology","first-page":"1","article-title":"Carcinoid heart disease: prognostic value of 5-hydroxyindoleacetic acid levels and impact on survival: a systematic literature review","volume":"111","author":"Buchanan-Hughes A","year":"2021","unstructured":"Buchanan-Hughes A, Pashley A, Feuilly M, Carcinoid heart disease: prognostic value of 5-hydroxyindoleacetic acid levels and impact on survival: a systematic literature review. Neuroendocrinology 2021;111:1\u201315."},{"key":"B16","series-title":"J Neuroendocrinol","first-page":"e13146","article-title":"European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease","volume":"34","author":"Grozinsky-Glasberg S","year":"2022","unstructured":"Grozinsky-Glasberg S, Davar J, Hofland J, European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease. J Neuroendocrinol 2022;34:e13146."},{"key":"B17","series-title":"J Amer Statist Assoc","first-page":"457","article-title":"Non-parametric estimation from incomplete observations","volume":"53","author":"Kaplan EL","year":"1958","unstructured":"Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Amer Statist Assoc 1958;53:457\u2013481."},{"key":"B18","series-title":"J Royal Stat Soc Series B Stat Methodol","first-page":"187","article-title":"Regression models and life tables (with discussion)","volume":"34","author":"Cox DR","year":"1972","unstructured":"Cox DR. Regression models and life tables (with discussion). J Royal Stat Soc Series B Stat Methodol 1972;34:187\u2013220."},{"key":"B19","article-title":"Flexible imputation of missing data","author":"van Buuren S","unstructured":"van Buuren S. Flexible imputation of missing data. Accessed November 21, 2025. Available at: https:\/\/stefvanbuuren.name\/fimd"},{"key":"B20","series-title":"Stat Med","first-page":"1982","article-title":"Imputing missing covariate values for the Cox model","volume":"28","author":"White IR","year":"2009","unstructured":"White IR, Royston P. Imputing missing covariate values for the Cox model. Stat Med 2009;28:1982\u20131998."},{"key":"B21","series-title":"Cancers (Basel)","first-page":"3272","article-title":"Survival trends in patients with small intestinal neuroendocrine tumours \u2013 a cohort study in Central Norway","volume":"15","author":"Folkestad O","year":"2023","unstructured":"Folkestad O, Hauso \u00d8, Mj\u00f8nes P, Survival trends in patients with small intestinal neuroendocrine tumours \u2013 a cohort study in Central Norway. Cancers (Basel) 2023;15:3272."},{"key":"B22","series-title":"Br J Surg","first-page":"1617","article-title":"Survival and prognostic factors in patients with small bowel carcinoid tumour","volume":"98","author":"Landerholm K","year":"2011","unstructured":"Landerholm K, Zar N, Andersson RE, Survival and prognostic factors in patients with small bowel carcinoid tumour. Br J Surg 2011;98:1617\u20131624."},{"key":"B23","series-title":"J Clin Oncol","first-page":"Abstract LBA588","article-title":"[177Lu] Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: primary analysis of the phase 3 randomized NETTER-2 study","volume":"42","author":"Singh S","year":"2024","unstructured":"Singh S, Halperin DM, Myrehaug S, [177Lu] Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: primary analysis of the phase 3 randomized NETTER-2 study. J Clin Oncol 2024;42(Suppl):Abstract LBA588."},{"key":"B24","series-title":"Cancer Epidemiol","first-page":"102197","article-title":"Incidence and prognosis of patients with small intestinal neuroendocrine tumors in a population based nationwide study","volume":"79","author":"Snorradottir S","year":"2022","unstructured":"Snorradottir S, Asgeirsdottir A, R\u00f6gnvaldsson S, Incidence and prognosis of patients with small intestinal neuroendocrine tumors in a population based nationwide study. Cancer Epidemiol 2022;79:102197."},{"key":"B25","series-title":"Neuroendocrinology","first-page":"265","article-title":"Clinicopathologic characteristics and survival of patients with gastroenteropancreatic neuroendocrine neoplasm in a multi-ethnic Asian institution","volume":"108","author":"Tai WM","year":"2019","unstructured":"Tai WM, Tan SH, Tan DMY, Clinicopathologic characteristics and survival of patients with gastroenteropancreatic neuroendocrine neoplasm in a multi-ethnic Asian institution. Neuroendocrinology 2019;108:265\u2013277."},{"key":"B26","series-title":"Am J Gastroenterol","first-page":"1464","article-title":"A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress","volume":"102","author":"Modlin IM","year":"2007","unstructured":"Modlin IM, Champaneria MC, Chan AK, Kidd M. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Am J Gastroenterol 2007;102:1464\u20131473."},{"key":"B27","series-title":"World J Surg","first-page":"2482","article-title":"Update on incidence, prevalence, treatment and survival of patients with small bowel neuroendocrine neoplasms in the Netherlands","volume":"45","author":"Ka\u00e7maz E","year":"2021","unstructured":"Ka\u00e7maz E, Sarasqueta AF, van Eeden S, Update on incidence, prevalence, treatment and survival of patients with small bowel neuroendocrine neoplasms in the Netherlands. World J Surg 2021;45:2482\u20132491."},{"key":"B28","series-title":"Neuroendocrinology","first-page":"471","article-title":"Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut","volume":"89","author":"Strosberg J","year":"2009","unstructured":"Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 2009;89:471\u2013476."},{"key":"B29","series-title":"Ann Oncol","first-page":"746","article-title":"Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors","volume":"27","author":"van Adrichem RC","year":"2016","unstructured":"van Adrichem RC, Kamp K, Vandamme T, Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors. Ann Oncol 2016;27:746\u2013747."},{"key":"B30","series-title":"J Endocrinol Invest","first-page":"959","article-title":"Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study","volume":"47","author":"Ruggeri RM","year":"2024","unstructured":"Ruggeri RM, Altieri B, Razzore P, Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study. J Endocrinol Invest 2024;47:959\u2013971."},{"key":"B31","series-title":"J Clin Oncol","first-page":"3063","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao JC","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063\u20133072."},{"key":"B32","series-title":"Clin Gastroenterol Hepatol","first-page":"820","article-title":"Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors","volume":"6","author":"Arnold R","year":"2008","unstructured":"Arnold R, Wilke A, Rinke A, Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008;6:820\u2013827."},{"key":"B33","series-title":"Endocr Relat Cancer","first-page":"R11","article-title":"Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame","volume":"25","author":"Marotta V","year":"2018","unstructured":"Marotta V, Zatelli MC, Sciammarella C, Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocr Relat Cancer 2018;25:R11\u201329."},{"key":"B34","series-title":"Eur J Gastroenterol Hepatol","first-page":"527","article-title":"The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases","volume":"27","author":"Han X","year":"2015","unstructured":"Han X, Zhang C, Tang M, The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases. Eur J Gastroenterol Hepatol 2015;27:527\u2013535."},{"key":"B35","series-title":"Dig Dis Sci","first-page":"877","article-title":"Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors","volume":"51","author":"Clancy TE","year":"2006","unstructured":"Clancy TE, Sengupta TP, Paulus J, Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig Dis Sci 2006;51:877\u2013884."},{"key":"B36","series-title":"Ann Surg Oncol","first-page":"2319","article-title":"Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database","volume":"24","author":"Fairweather M","year":"2017","unstructured":"Fairweather M, Swanson R, Wang J, Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database. Ann Surg Oncol 2017;24:2319\u20132325."},{"key":"B37","series-title":"Eur J Endocrinol","first-page":"361","article-title":"Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours","volume":"175","author":"Zandee WT","year":"2016","unstructured":"Zandee WT, Kamp K, Van Adrichem RCS, Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours. Eur J Endocrinol 2016;175:361\u2013366."},{"key":"B38","series-title":"Clin Endocrinol (Oxf)","first-page":"165","article-title":"Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours","volume":"87","author":"Zandee WT","year":"2017","unstructured":"Zandee WT, van Adrichem RC, Kamp K, Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours. Clin Endocrinol (Oxf) 2017;87:165\u2013170."},{"key":"B39","series-title":"J Neuroendocrinol","first-page":"e13262","article-title":"Carcinoid heart disease in patients with midgut neuroendocrine tumours","volume":"35","author":"Delhomme C","year":"2023","unstructured":"Delhomme C, Walter T, Arangalage D, Carcinoid heart disease in patients with midgut neuroendocrine tumours. J Neuroendocrinol 2023;35:e13262."},{"key":"B40","series-title":"J Neuroendocrinol","first-page":"e13199","article-title":"Four decades of experience with carcinoid heart disease: an analysis of 84 patients","volume":"34","author":"Levy S","year":"2022","unstructured":"Levy S, Korse CE, de Groot ACA, Four decades of experience with carcinoid heart disease: an analysis of 84 patients. J Neuroendocrinol 2022;34:e13199."},{"key":"B1","series-title":"JAMA Oncol","first-page":"1335","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari A","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017;3:1335\u20131342"},{"key":"B2","series-title":"Lancet Reg Health Eur","first-page":"100510","article-title":"Incidence and survival of neuroendocrine neoplasia in England 1995-2018: a retrospective, population-based study","volume":"23","author":"White BE","year":"2022","unstructured":"White BE, Rous B, Chandrakumaran K, Incidence and survival of neuroendocrine neoplasia in England 1995-2018: a retrospective, population-based study. Lancet Reg Health Eur 2022;23:100510."},{"key":"B3","series-title":"Lancet Oncol","first-page":"525","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin DM","year":"2017","unstructured":"Halperin DM, Shen C, Dasari A, Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol 2017;18:525\u2013534."},{"key":"B4","series-title":"J Oncol","first-page":"8341426","article-title":"Update on pathophysiology, treatment, and complications of carcinoid syndrome","volume":"2020","author":"Clement D","year":"2020","unstructured":"Clement D, Ramage J, Srirajaskanthan R. Update on pathophysiology, treatment, and complications of carcinoid syndrome. J Oncol 2020;2020:8341426."},{"key":"B5","series-title":"Neuroendocrinology","first-page":"263","article-title":"Carcinoid heart disease: from pathophysiology to treatment \u2013 \u2018something in the way it moves.\u2019","volume":"101","author":"Grozinsky-Glasberg S","year":"2015","unstructured":"Grozinsky-Glasberg S, Grossman AB, Gross DJ. Carcinoid heart disease: from pathophysiology to treatment \u2013 \u2018something in the way it moves.\u2019 Neuroendocrinology 2015;101:263\u2013273."},{"key":"B6","series-title":"Endocr Rev","first-page":"351","article-title":"What is carcinoid syndrome? A critical appraisal of its proposed mediators","volume":"45","author":"Mulders MCF","year":"2024","unstructured":"Mulders MCF, de Herder WW, Hofland J. What is carcinoid syndrome? A critical appraisal of its proposed mediators. Endocr Rev 2024;45:351\u2013360."},{"key":"B7","series-title":"J Chromatogr B Biomed Sci Appl","first-page":"33","article-title":"Clinical chemistry of serotonin and metabolites","volume":"747","author":"Kema IP","year":"2000","unstructured":"Kema IP, de Vries EG, Muskiet FA. Clinical chemistry of serotonin and metabolites. J Chromatogr B Biomed Sci Appl 2000;747:33\u201348."},{"key":"B8","series-title":"Eur J Cancer","first-page":"1975","article-title":"Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry","volume":"49","author":"Korse CM","year":"2013","unstructured":"Korse CM, Taal BG, van Velthuysen ML, Visser O. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. Eur J Cancer 2013;49:1975\u20131983."},{"key":"B9","series-title":"Eur J Cancer","first-page":"252","article-title":"Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: a population-based study","volume":"172","author":"Pole\u00e9 IN","year":"2022","unstructured":"Pole\u00e9 IN, Hermans BCM, van der Zwan JM, Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: a population-based study. Eur J Cancer 2022;172:252\u2013263."},{"key":"B10","series-title":"Am J Clin Oncol","first-page":"668","article-title":"Competing mortality in patients with neuroendocrine tumors","volume":"42","author":"Low SK","year":"2019","unstructured":"Low SK, Giannis D, Bahaie NS, Competing mortality in patients with neuroendocrine tumors. Am J Clin Oncol 2019;42:668\u2013674."},{"key":"B11","series-title":"Pancreas","first-page":"47","article-title":"Causes of death after neuroendocrine tumors diagnosis: a US population-based analysis","volume":"50","author":"Sonbol MB","year":"2021","unstructured":"Sonbol MB, Saad AM, Gonzalez-Velez M, Causes of death after neuroendocrine tumors diagnosis: a US population-based analysis. Pancreas 2021;50:47\u201353."},{"key":"B12","series-title":"J Natl Compr Canc Netw","first-page":"935","article-title":"Risk of cancer-specific death for patients diagnosed with neuroendocrine tumors: a population-based analysis","volume":"19","author":"Hallet J","year":"2021","unstructured":"Hallet J, Law C, Singh S, Risk of cancer-specific death for patients diagnosed with neuroendocrine tumors: a population-based analysis. J Natl Compr Canc Netw 2021;19:935\u2013944."},{"key":"B13","series-title":"Neuroendocrinology","first-page":"547","article-title":"Clinical features and prognosis of patients with carcinoid syndrome and carcinoid heart disease: a retrospective multicentric study of 276 patients","volume":"112","author":"Fijalkowski R","year":"2022","unstructured":"Fijalkowski R, Reher D, Rinke A, Clinical features and prognosis of patients with carcinoid syndrome and carcinoid heart disease: a retrospective multicentric study of 276 patients. Neuroendocrinology 2022;112:547\u2013554."},{"key":"B14","series-title":"ESMO Open","first-page":"103959","article-title":"Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers","volume":"9","author":"Algeri L","year":"2024","unstructured":"Algeri L, Falkman L, Spada F, Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers. ESMO Open 2024;9:103959."},{"key":"B15","series-title":"Neuroendocrinology","first-page":"1","article-title":"Carcinoid heart disease: prognostic value of 5-hydroxyindoleacetic acid levels and impact on survival: a systematic literature review","volume":"111","author":"Buchanan-Hughes A","year":"2021","unstructured":"Buchanan-Hughes A, Pashley A, Feuilly M, Carcinoid heart disease: prognostic value of 5-hydroxyindoleacetic acid levels and impact on survival: a systematic literature review. Neuroendocrinology 2021;111:1\u201315."},{"key":"B16","series-title":"J Neuroendocrinol","first-page":"e13146","article-title":"European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease","volume":"34","author":"Grozinsky-Glasberg S","year":"2022","unstructured":"Grozinsky-Glasberg S, Davar J, Hofland J, European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease. J Neuroendocrinol 2022;34:e13146."},{"key":"B17","series-title":"J Amer Statist Assoc","first-page":"457","article-title":"Non-parametric estimation from incomplete observations","volume":"53","author":"Kaplan EL","year":"1958","unstructured":"Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Amer Statist Assoc 1958;53:457\u2013481."},{"key":"B18","series-title":"J Royal Stat Soc Series B Stat Methodol","first-page":"187","article-title":"Regression models and life tables (with discussion)","volume":"34","author":"Cox DR","year":"1972","unstructured":"Cox DR. Regression models and life tables (with discussion). J Royal Stat Soc Series B Stat Methodol 1972;34:187\u2013220."},{"key":"B19","article-title":"Flexible imputation of missing data","author":"van Buuren S","unstructured":"van Buuren S. Flexible imputation of missing data. Accessed November 21, 2025. Available at: https:\/\/stefvanbuuren.name\/fimd"},{"key":"B20","series-title":"Stat Med","first-page":"1982","article-title":"Imputing missing covariate values for the Cox model","volume":"28","author":"White IR","year":"2009","unstructured":"White IR, Royston P. Imputing missing covariate values for the Cox model. Stat Med 2009;28:1982\u20131998."},{"key":"B21","series-title":"Cancers (Basel)","first-page":"3272","article-title":"Survival trends in patients with small intestinal neuroendocrine tumours \u2013 a cohort study in Central Norway","volume":"15","author":"Folkestad O","year":"2023","unstructured":"Folkestad O, Hauso \u00d8, Mj\u00f8nes P, Survival trends in patients with small intestinal neuroendocrine tumours \u2013 a cohort study in Central Norway. Cancers (Basel) 2023;15:3272."},{"key":"B22","series-title":"Br J Surg","first-page":"1617","article-title":"Survival and prognostic factors in patients with small bowel carcinoid tumour","volume":"98","author":"Landerholm K","year":"2011","unstructured":"Landerholm K, Zar N, Andersson RE, Survival and prognostic factors in patients with small bowel carcinoid tumour. Br J Surg 2011;98:1617\u20131624."},{"key":"B23","series-title":"J Clin Oncol","first-page":"Abstract LBA588","article-title":"[177Lu] Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: primary analysis of the phase 3 randomized NETTER-2 study","volume":"42","author":"Singh S","year":"2024","unstructured":"Singh S, Halperin DM, Myrehaug S, [177Lu] Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: primary analysis of the phase 3 randomized NETTER-2 study. J Clin Oncol 2024;42(Suppl):Abstract LBA588."},{"key":"B24","series-title":"Cancer Epidemiol","first-page":"102197","article-title":"Incidence and prognosis of patients with small intestinal neuroendocrine tumors in a population based nationwide study","volume":"79","author":"Snorradottir S","year":"2022","unstructured":"Snorradottir S, Asgeirsdottir A, R\u00f6gnvaldsson S, Incidence and prognosis of patients with small intestinal neuroendocrine tumors in a population based nationwide study. Cancer Epidemiol 2022;79:102197."},{"key":"B25","series-title":"Neuroendocrinology","first-page":"265","article-title":"Clinicopathologic characteristics and survival of patients with gastroenteropancreatic neuroendocrine neoplasm in a multi-ethnic Asian institution","volume":"108","author":"Tai WM","year":"2019","unstructured":"Tai WM, Tan SH, Tan DMY, Clinicopathologic characteristics and survival of patients with gastroenteropancreatic neuroendocrine neoplasm in a multi-ethnic Asian institution. Neuroendocrinology 2019;108:265\u2013277."},{"key":"B26","series-title":"Am J Gastroenterol","first-page":"1464","article-title":"A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress","volume":"102","author":"Modlin IM","year":"2007","unstructured":"Modlin IM, Champaneria MC, Chan AK, Kidd M. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Am J Gastroenterol 2007;102:1464\u20131473."},{"key":"B27","series-title":"World J Surg","first-page":"2482","article-title":"Update on incidence, prevalence, treatment and survival of patients with small bowel neuroendocrine neoplasms in the Netherlands","volume":"45","author":"Ka\u00e7maz E","year":"2021","unstructured":"Ka\u00e7maz E, Sarasqueta AF, van Eeden S, Update on incidence, prevalence, treatment and survival of patients with small bowel neuroendocrine neoplasms in the Netherlands. World J Surg 2021;45:2482\u20132491."},{"key":"B28","series-title":"Neuroendocrinology","first-page":"471","article-title":"Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut","volume":"89","author":"Strosberg J","year":"2009","unstructured":"Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 2009;89:471\u2013476."},{"key":"B29","series-title":"Ann Oncol","first-page":"746","article-title":"Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors","volume":"27","author":"van Adrichem RC","year":"2016","unstructured":"van Adrichem RC, Kamp K, Vandamme T, Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors. Ann Oncol 2016;27:746\u2013747."},{"key":"B30","series-title":"J Endocrinol Invest","first-page":"959","article-title":"Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study","volume":"47","author":"Ruggeri RM","year":"2024","unstructured":"Ruggeri RM, Altieri B, Razzore P, Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study. J Endocrinol Invest 2024;47:959\u2013971."},{"key":"B31","series-title":"J Clin Oncol","first-page":"3063","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao JC","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063\u20133072."},{"key":"B32","series-title":"Clin Gastroenterol Hepatol","first-page":"820","article-title":"Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors","volume":"6","author":"Arnold R","year":"2008","unstructured":"Arnold R, Wilke A, Rinke A, Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008;6:820\u2013827."},{"key":"B33","series-title":"Endocr Relat Cancer","first-page":"R11","article-title":"Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame","volume":"25","author":"Marotta V","year":"2018","unstructured":"Marotta V, Zatelli MC, Sciammarella C, Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocr Relat Cancer 2018;25:R11\u201329."},{"key":"B34","series-title":"Eur J Gastroenterol Hepatol","first-page":"527","article-title":"The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases","volume":"27","author":"Han X","year":"2015","unstructured":"Han X, Zhang C, Tang M, The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases. Eur J Gastroenterol Hepatol 2015;27:527\u2013535."},{"key":"B35","series-title":"Dig Dis Sci","first-page":"877","article-title":"Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors","volume":"51","author":"Clancy TE","year":"2006","unstructured":"Clancy TE, Sengupta TP, Paulus J, Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig Dis Sci 2006;51:877\u2013884."},{"key":"B36","series-title":"Ann Surg Oncol","first-page":"2319","article-title":"Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database","volume":"24","author":"Fairweather M","year":"2017","unstructured":"Fairweather M, Swanson R, Wang J, Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database. Ann Surg Oncol 2017;24:2319\u20132325."},{"key":"B37","series-title":"Eur J Endocrinol","first-page":"361","article-title":"Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours","volume":"175","author":"Zandee WT","year":"2016","unstructured":"Zandee WT, Kamp K, Van Adrichem RCS, Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours. Eur J Endocrinol 2016;175:361\u2013366."},{"key":"B38","series-title":"Clin Endocrinol (Oxf)","first-page":"165","article-title":"Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours","volume":"87","author":"Zandee WT","year":"2017","unstructured":"Zandee WT, van Adrichem RC, Kamp K, Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours. Clin Endocrinol (Oxf) 2017;87:165\u2013170."},{"key":"B39","series-title":"J Neuroendocrinol","first-page":"e13262","article-title":"Carcinoid heart disease in patients with midgut neuroendocrine tumours","volume":"35","author":"Delhomme C","year":"2023","unstructured":"Delhomme C, Walter T, Arangalage D, Carcinoid heart disease in patients with midgut neuroendocrine tumours. J Neuroendocrinol 2023;35:e13262."},{"key":"B40","series-title":"J Neuroendocrinol","first-page":"e13199","article-title":"Four decades of experience with carcinoid heart disease: an analysis of 84 patients","volume":"34","author":"Levy S","year":"2022","unstructured":"Levy S, Korse CE, de Groot ACA, Four decades of experience with carcinoid heart disease: an analysis of 84 patients. J Neuroendocrinol 2022;34:e13199."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/4\/article-e257130.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/4\/article-e257130.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/4\/article-e257130.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:08:09Z","timestamp":1775740089000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/4\/article-e257130.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":80,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7130","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}